These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21495219)

  • 1. Tackling hepatitis C: a tale of two countries.
    Morris K
    Lancet; 2011 Apr; 377(9773):1227-8. PubMed ID: 21495219
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C infection among injecting drug users in Scotland: stemming the flow.
    Goldberg D; Taylor A; Hutchinson S; McMenamin J
    Scott Med J; 2000 Oct; 45(5):131-2. PubMed ID: 11130293
    [No Abstract]   [Full Text] [Related]  

  • 3. Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase.
    Copeman M
    Med J Aust; 2003 Jul; 179(2):119; author reply 119. PubMed ID: 12864712
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high.
    Goldberg D; Cameron S; McMenamin J
    Commun Dis Public Health; 1998 Jun; 1(2):95-7. PubMed ID: 9644121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access to hepatitis C care for people who inject drugs and people in prisons.
    Oru E; Verster A
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):662-663. PubMed ID: 31362917
    [No Abstract]   [Full Text] [Related]  

  • 6. Who: four ways to reduce hepatitis infections in people who inject drugs.
    Cent Eur J Public Health; 2012 Sep; 20(3):207. PubMed ID: 23285521
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis C: who is at risk and how do we identify them?
    Goldberg D; Anderson E
    J Viral Hepat; 2004 Sep; 11 Suppl 1():12-8. PubMed ID: 15357858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C prevention and true harm reduction.
    Madden A; Cavalieri W
    Int J Drug Policy; 2007 Oct; 18(5):335-7. PubMed ID: 17854719
    [No Abstract]   [Full Text] [Related]  

  • 9. [The efficacy of needle exchange programs in the prevention of HIV and hepatitis infection among injecting drug users].
    Takács IG; Demetrovics Z
    Psychiatr Hung; 2009; 24(4):264-81. PubMed ID: 19949245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C screening and management practices: a survey of drug treatment and syringe exchange programs in New York City.
    Pratt CC; Paone D; Carter RJ; Layton MC
    Am J Public Health; 2002 Aug; 92(8):1254-6. PubMed ID: 12144980
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis C action plan for Scotland: phase II (May 2008-March 2011).
    Goldberg D; Brown G; Hutchinson S; Dillon J; Taylor A; Howie G; Ahmed S; Roy K; King M;
    Euro Surveill; 2008 May; 13(21):. PubMed ID: 18761968
    [No Abstract]   [Full Text] [Related]  

  • 12. Injecting drug use in India and the need for policy and program change.
    Panda S; Kumar MS
    Int J Drug Policy; 2016 Nov; 37():115-116. PubMed ID: 27771524
    [No Abstract]   [Full Text] [Related]  

  • 13. Eradication of hepatitis C infection: the importance of targeting people who inject drugs.
    Hellard M; Doyle JS; Sacks-Davis R; Thompson AJ; McBryde E
    Hepatology; 2014 Feb; 59(2):366-9. PubMed ID: 23873507
    [No Abstract]   [Full Text] [Related]  

  • 14. Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase.
    Law MG; Batey RG
    Med J Aust; 2003 Mar; 178(5):197-8. PubMed ID: 12603178
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prevention of hepatitis C. How to update the pioneer work done by Eugène Jamot?].
    Coton T
    Presse Med; 2003 Sep; 32(29):1349-50. PubMed ID: 14534495
    [No Abstract]   [Full Text] [Related]  

  • 16. [Modifications of epidemiological characteristics of hepatitis C].
    Roudot-Thoraval F
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B138-43. PubMed ID: 12180281
    [No Abstract]   [Full Text] [Related]  

  • 17. Science versus politics: the need for supervised injection facilities in Montreal, Canada.
    Jozaghi E
    Int J Drug Policy; 2012 Sep; 23(5):420-1. PubMed ID: 22818890
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing hepatitis C virus transmission in Australians who inject drugs.
    Watson KJ
    Med J Aust; 2000 Jan; 172(2):55-6. PubMed ID: 10738472
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: "Syringe exchange and risk of infection with hepatitis B and C viruses".
    Voth EA
    Am J Epidemiol; 2000 Jan; 151(2):207-8. PubMed ID: 10645825
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.